Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
ImmunoGen revenue increased from $82.3 million in 2019 to $132.3 million in 2020, a (60.8%) increase.
Annual Revenue ($)
ImmunoGen revenue was $132.3 m in FY, 2020 which is a (60.8%) year over year increase from the previous period.
Quarterly Revenue ($)
Annual Growth Rate (%)
Revenue Breakdown
Business Segment
ImmunoGen revenue breakdown by business segment: 51.8% from Non-Cash Royalty Revenue, 48.2% from License and Milestone Fees and 0.0% from Other
| FY, 2019 | FY, 2020 | FY, 2018 | |
|---|---|---|---|
| Non-Cash Royalty Revenue | $47.42 m | $68.53 m | $32.15 m |
| License and Milestone Fees | $34.79 m | $63.74 m | $15.28 m |
| Clinical Materials Revenue | $4.64 m | ||
| Research and Development Support | $68 k | $28 k | $1.38 m |
Need Data?
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.